Full-Time
Global Product Development Lead
Early-Stage
Telix Pharmaceuticals
1,001-5,000 employees
Develops targeted radiation diagnostics and therapies
No salary listed
Remote in USA
Remote
PhD
 Biology & Biotech (1) |
|---|
Get referred to Telix Pharmaceuticals
See people who can refer or advise you
- Postgraduate qualifications in science or life sciences (ideally PhD) required
- 10+ years’ pharmaceutical/biotechnology industry experience including direct experience in drug development (ideally in oncology) required
- 3+ years’ project and budget management experience
- An understanding of the regulatory environment in the US, EU and APAC pertaining to drug development
- Experience working as part of, and also managing, a cross-functional team
- Work as part of a cross-functional team to create/manage a Target Product Profile and Product Development plan for the targeted therapy in solid tumours
- Lead cross-functional teams to deliver the program development milestones up to the end of Phase 2 clinical evaluation within project timelines and budget
- Act as the primary point of contact for the program and ensure that excellent communication is maintained both internally and externally
- Oversight of a Project Manager to ensure application of project management best practice
- Complete oversight of the delivery of product development plans, more specifically:
- Maintenance of up-to-date documentation of product positioning and target product profile
- Progress tracking of all activities against the development plan and notification of potential delays and/or other changes
- Documentation and tracking of the Program budget; working with Finance and the project manager to ensure contracts and costs are recorded in an accurate and timely manner
- Work with senior management to assess product development risks and compile risk mitigation and scenario plans
- Conduct regular reviews to ensure appropriate Program documentation is in place and to monitor project progress, scope, timelines and budget
- Ensuring all Program Team members and the Executive are kept informed of project status, costs and risks
- Supporting Project Managers in preparing periodic reports to internal stakeholders, including senior management, on the status and progress of the Program
- Contribute to the definition and delivery of Corporate Objectives
- Preparing timely and accurate reports for Management
- Maintaining current awareness of Program-related scientific, clinical and commercial functional knowledge
- Represent the program team at internal and external meetings
- Inclusive mindset: Demonstrate an understanding and appreciation for diversity, and actively work to create an inclusive environment where everyone feels valued and respected
- Creativity and innovation: Possess a willingness to think outside the box and come up with unique and creative solutions to challenges
- Commitment to excellence: Take pride in your work and consistently strive for excellence in everything you do
- Results-oriented: Driven to achieve goals and objectives, with a strong focus on delivering measurable results
- Ethical behavior: Act with integrity and demonstrate a commitment to ethical behavior in all interactions with colleagues and stakeholders
- Adaptability: Comfortable working in a dynamic environment, able to adjust to changing priorities, and willing to take on new challenges
- Strong communication skills: Able to communicate effectively with colleagues and stakeholders at all levels, using clear and concise language
- Collaboration: Work effectively as part of a team, actively sharing knowledge and expertise to achieve common goals
- Resilience: Demonstrate the ability to bounce back from setbacks and persevere in the face of challenges
- Continuous learning: Show a commitment to ongoing learning and professional development, continually seeking out opportunities to expand your knowledge and skills
- Attention to Detail: Have a strong attention to detail and be able to pick up errors before they become issues whilst also maintaining a helicopter view and be able to prioritise
Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Get referred to Telix Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit US$247 million, tracking toward over US$1 billion annual revenue.
- Regeneron paid US$40 million upfront, validating Telix's radiopharma platform and expanding milestone upside.
- FDA aligned on ProstACT Global Part 2, while Pixclara gained a September 11, 2026 PDUFA date.
What critics are saying
- January 2026 class actions and the 2025 SEC subpoena attack Telix disclosures and credibility.
- August 2025 FDA CRL on Zircaix exposed CMC failures at third-party manufacturers.
- September 11, 2026 Pixclara PDUFA and Zircaix resubmission can derail if CMC fixes fail.
What makes Telix Pharmaceuticals unique
- Illuccix and Gozellix create Telix's two-product PSMA imaging franchise across 22 countries.
- July 2026 ProstACT Global data support TLX591-Tx's theranostic selection and durable tumor targeting.
- North Melbourne, Brussels, and Yokohama facilities tighten isotope supply and patient-dose logistics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%Telix to host R&D Day in New York City on September 22, 2026. Discover more Company Earnings Business Formation Stocks & Bonds 3 hours ago August 6, 2026 MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional investors and analysts are invited to register to attend the in-person session, which will feature a comprehensive overview of Telix's therapeutic and precision medicine pipeline, as well as key scientific, clinical and strategic developments across the portfolio. Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer, Dr. David N. Cade; CEO Therapeutics, Richard Valeix; CEO Precision Medicine, Kevin Richardson and Vice President Discovery Sciences, Dr. Michael Wheatcroft. The program will also feature presentations from key opinion leaders who will provide their perspectives on the clinical and scientific opportunities. Advance registration is required for in-person attendance. Additional event details, including the venue, agenda and presentation materials, will be provided to registered attendees. Capital Markets Day to be hosted in Melbourne on November 4, 2026 - Save the Date Discover more Luxury Goods Business Finance Geographic Reference Telix will also host a Capital Markets Day in Melbourne on Wednesday, November 4, 2026. Telix management will provide updates on the Company's strategy, growth outlook, financial targets and key business priorities. Further details will be provided in a separate announcement. Note: These events are for qualified institutional investors and analysts. About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. Telix's commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix(R)(kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix(R)(kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 ([177] Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx ([131] I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium ([177] Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with its risk factors, as disclosed in its most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC, or on its website. Discover more Luxury Vehicles The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the(R) or(TM) symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. The information provided in this article was created by Cision PR Newswire, its news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of ThailandChina.
TLX591-Tx ProstACT SELECT study published in Cancers journal. Melbourne (Australia) and Indianapolis, IN (United States) | July 22, 2026 * Peer-reviewed publication of ProstACT SELECT[1] results confirm the utility of [68] Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach[2]. * Consistent with previously reported results[3], the publication highlights TLX591-Tx's clinical differentiation and safety profile. * TLX591-Tx, Telix's lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study[4] for advanced metastatic prostate cancer. Telix today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 ([177] Lu) rosopatamab tetraxetan), Telix's first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study's scientific purpose was to evaluate lesion concordance between [68] Ga-PSMA-PET[5] and multi-time point SPECT[6] imaging for patient selection using a "theranostic" approach. The publication highlights TLX591-Tx's differentiated clinical profile, including an intensified dosing schedule, prolonged tumor retention and low exocrine (salivary) gland irradiation. The authors also concluded that in a heterogeneous population representative of a real-world setting, TLX591-Tx therapy in combination with standard of care (SOC) demonstrated a manageable and predictable safety profile, and indicative efficacy with a median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients. Nat Lenzo, MD, Nuclear Medicine Oncologist and Principal Investigator on the ProstACT SELECT study commented, "A key objective of ProstACT SELECT was to determine whether PSMA-PET imaging could reliably identify patients suitable for TLX591-Tx therapy, and the results clearly support this approach. The results provide compelling evidence that the PSMA-PET imaging agent and TLX591-Tx are targeting the same disease sites, supporting the ongoing ProstACT Global trial for mCRPC[7], where there remains significant unmet need for additional treatment options." David N. Cade, MD, Group Chief Medical Officer, Telix, said, "The publication of ProstACT SELECT data further strengthens the scientific foundation for Telix's lead therapeutic candidate, TLX591-Tx. The peer-reviewed results support our patient-selection strategy and demonstrate a differentiated pharmacologic profile characterized by durable tumor targeting, hepatobiliary clearance, and a manageable safety profile. Telix is further evaluating TLX591-Tx in the international multi-center Phase 3 ProstACT Global study, where we aim to meaningfully improve outcomes for patients living with advanced prostate cancer." About ProstACT SELECT The purpose of the ProstACT SELECT trial was to evaluate the utility of [68] Ga-PSMA-PET imaging (Illuccix) to select patients for TLX591-Tx rADC therapy. The primary objectives were to determine whole body biodistribution and organ radiation dosimetry and assess the safety and tolerability of TLX591-Tx in patients with advanced mCRPC. rPFS was a secondary study objective. TLX591-Tx has not received a marketing authorization in any jurisdiction [2] Lenzo et al. Cancers. 2026. [3] Telix ASX disclosures October 19, 2023 and May 31, 2024. [5] Imaging of prostate-specific membrane antigen with positron emission tomography. [6] Single-photon emission computed tomography. [7] Metastatic castration-resistant prostate cancer.
Telix posts strong quarter as revenue nears billion dollar annual run rate. Telix Pharmaceuticals (ASX:TLX) has reported robust commercial momentum in the quarter ended June 30, 2026, with group revenue of US$247 million, up 21 per cent year over year and 7 per cent from the prior quarter. Precision Medicine led growth with US$202 million in revenue, a 30 per cent increase year over year and 9 per cent sequentially, while Telix Manufacturing Solutions contributed US$45 million. The company said revenue is tracking toward the upper end of its financial year 2026 guidance. It expects revenue and other income to exceed US$1 billion, including a US$40 million non-refundable payment from Regeneron. The company said the quarter featured several regulatory and clinical advances across both the Therapeutics and Precision Medicine portfolios. The United States Food and Drug Administration provided alignment that allows the ProstACT global Phase 3 study of TLX591 Tx to advance to Part 2 in the U.S. Enrollment is progressing in multiple regions, and the program has regulatory approval to commence in China. The OPTIMAL PSMA program completed enrollment in its OPTIMAL PSMA study and has begun dosing in the OPTIMAL-e Phase 2 study for earlier-stage disease. Telix also dosed the first patient in LUTEON, a pivotal trial of TLX250 Tx in clear cell renal cell carcinoma, and enrolled initial cohorts in IPAX BrIGHT, a pivotal trial of TLX101 Tx in recurrent glioblastoma. On the imaging side, Telix reported rapid BiPASS enrollment for Illuccix and Gozellix, and completed patient enrollment in Japan for the registrational study of TLX591 Px with a New Drug Application in preparation. The company said the FDA accepted the resubmitted NDA for Pixclara and granted a PDUFA goal date of September 11, 2026. Telix is also advancing its BLA resubmission for Zircaix and nearing completion of final CMC documentation. Commercial and operational expansion continued with new manufacturing capacity and supply chain investments. Telix recently opened a Telix Manufacturing Solutions (TMS) facility in North Melbourne in partnership with the Melbourne Theranostic Innovation Centre and completed a first GMP production run at TMS Brussels South. The company installed an ARTMS QUANTM irradiation system at TMS Yokohama as part of its plan to scale isotope production globally. Corporate developments during the quarter included a strategic collaboration with Regeneron to jointly develop next-generation radiopharmaceutical therapies and the receipt of an initial US$40 million non-refundable payment. Telix also completed a refinancing by issuing US$600 million of convertible bonds due 2031 and repurchasing its 2029 bonds. Three new non-executive directors joined the board as part of succession planning. Managing Director and Group CEO Dr Christian Behrenbruch said, "We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value."
Telix Pharmaceuticals reported Q2 2026 revenue of US$247 million, up 7% quarter-over-quarter and 21% year-over-year. The company's Precision Medicine division generated US$202 million, rising 9% quarterly and 30% annually. Telix expects full-year 2026 revenue and other income to exceed US$1 billion, tracking towards the upper end of its US$950 million to US$970 million revenue guidance, plus US$40 million from Regeneron. The company updated its research and development expenditure guidance to US$230 million to US$270 million. The Melbourne-based radiopharmaceutical company achieved FDA alignment on its ProstACT Global Phase 3 study of TLX591-Tx in metastatic castration-resistant prostate cancer. Telix also announced a strategic collaboration with Regeneron to develop next-generation radiopharmaceutical therapies, initially focused on lung cancer. The company completed refinancing of its convertible bond structure, issuing US$600 million of new convertible bonds due 2031.
Telix opens radiopharmaceutical facility in Australia for cancer treatment. Recommended companies. Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer. Known as Telix Manufacturing Solutions North Melbourne (TMSNM), the site is described as the country's first purpose-built facility to combine radiochemistry laboratories, clinical manufacturing, patient dose administration, and imaging in one location. It aims to boost local capacity for radiopharmaceuticals, which are increasingly used to diagnose and treat cancer. The facility aims to address manufacturing capacity challenges and bring production and patient administration closer together. By integrating research, clinical trials, and patient treatment, the company aims to reduce the time needed to progress from early-stage trials to wider patient access. Melbourne Theranostic Innovation Centre (MTIC) will deliver patient care and research at the North Melbourne site. The collaboration between Telix and MTIC includes studies sponsored by Telix, investigator-led trials, and selected projects from external partners. Telix managing director and group CEO Dr Christian Behrenbruch said: "Radiopharmaceuticals are fast becoming an important part of cancer care, but manufacturing capacity for novel treatments, which needs to be near patients, remains a constraint in Australia. "This facility will allow us to move new treatments from research into the clinic and patient use more efficiently. It is also an investment in Australia's sovereign manufacturing capability and the specialist workforce needed to build a globally competitive radiopharmaceutical industry." MTIC founder, chair and chief medical officer professor Rod Hicks said: "Bringing these capabilities together will give clinicians faster access to novel radiopharmaceuticals and allow emerging technologies to be assessed in a real-world clinical setting. "It will help us select patients more precisely, measure treatment response and generate evidence more quickly as we evaluate new targets and next generation isotopes and treatment approaches." Telix disclosed that the new site will also provide training for nuclear medicine, radiochemistry, engineering, and clinical research roles. In February 2024, Telix signed an agreement to acquire US-based speciality radiopharmaceutical development and bioconjugation company IsoTherapeutics. Enter your email address so we can get in touch.